First Implant to Treat Opioid Addiction Gets FDA Approval
- Titan product delivers drug continuously for six months
- Treatment will be limited to stable patients on low doses
How Prescription Drugs Sparked America's Heroin Epidemic
This article is for subscribers only.
Titan Pharmaceuticals Inc. and partner Braeburn Pharmaceuticals won approval for the first implant in the U.S. to treat heroin and opioid painkiller addictions, which have reached epidemic levels.
The Food and Drug Administration cleared the product, Probuphine, for sale to treat addicts continuously for six months with the drug buprenorphine, according to a statement from the agency on Thursday.